On November 5, 2019 Genecast (Beijing) Technology reported that it closed a $43 million Series D financing to expand its non-invasive cancer diagnostic business (Press release, ChinaBio, NOV 5, 2019, View Source [SID1234550315]). Founded in 2014, Genecast has developed a circulating tumor DNA detection technology that provides individualized cancer diagnoses. The company offers oncology diagnostic products and services to China biopharmas, collaborating with more than 20 biopharmas and providing comprehensive pre-clinical and clinical testing services. The D round, which brings Genecast’s total VC backing to $93.5 million, was led by CICC Capital.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!